Financial Instruments and Fair Value Measurements - Convertible Promissory Note in Gate Neuroscience (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($) Director	Dec. 31, 2021 USD ($)	Sep. 30, 2022 USD ($) Director
Equity Investment
Equity and long-term investments	$ 489,111	$ 483,845	$ 489,111
Gate Neuroscience Member
Equity Investment
Number Of Common Stock Issued Description		The number of common stock shares to be issued in a qualified event shall be equal to the amount due on the conversion date divided by the lesser of a capped conversion price (the “Capped Conversion Price”) and the qualified event price (the “Qualified Event Price”). The Capped Conversion Price is calculated as $50.0 million divided by the number of shares of common stock outstanding at such time on a fully diluted basis. The Qualified Event Price is the price per share determined by the qualified event. A qualified financing is a sale or series of sales of preferred stock where (i) at least 50 percent of counterparties are not existing shareholders, (ii) net proceeds to Gate are at least $35.0 million, and (iii) the stated or implied equity valuation of Gate is at least $80.0 million. Shadow Preferred means preferred stock having identical rights, preferences and restrictions as the preferred stock that would be issued in a qualified financing.
Equity and long-term investments	15,400	$ 15,100	15,400
Unrealized gain from fair value changes in equity investments	$ 200		$ 300
Number of Investee's Board members currently representing the Company | Director	1		1
Number of the Investee's Board members | Director	3		3
Convertible Promissory Note Purchase Agreement | Gate Neuroscience Member
Equity Investment
Convertable notes Face Value		$ 15,000
Debt Instrument, Interest Rate, Effective Percentage		8.00%